Keywords: astellas, signs, fibrogen, anemia, deal, up, 2b

Astellas signs FibroGen anemia deal of up to $2B

Article | 08 May 2006

Japanese drug major Astellas has exclusively in-licensed USA-based FibroGen's hypoxia-inducible factor prolyl hydroxylase inhibitors for development and marketing for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Antihemophilic Factor

Recombinant

Coagulation Factor VIIa

Nystatin

Go to drug listing